Fang Jiansong, Wu Zengrui, Cai Chuipu, Wang Qi, Tang Yun, Cheng Feixiong
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine , 12 Jichang Road, Guangzhou 510405, China.
Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology , 130 Meilong Road, Shanghai 200237, China.
J Chem Inf Model. 2017 Nov 27;57(11):2657-2671. doi: 10.1021/acs.jcim.7b00216. Epub 2017 Oct 13.
Natural products with diverse chemical scaffolds have been recognized as an invaluable source of compounds in drug discovery and development. However, systematic identification of drug targets for natural products at the human proteome level via various experimental assays is highly expensive and time-consuming. In this study, we proposed a systems pharmacology infrastructure to predict new drug targets and anticancer indications of natural products. Specifically, we reconstructed a global drug-target network with 7,314 interactions connecting 751 targets and 2,388 natural products and built predictive network models via a balanced substructure-drug-target network-based inference approach. A high area under receiver operating characteristic curve of 0.96 was yielded for predicting new targets of natural products during cross-validation. The newly predicted targets of natural products (e.g., resveratrol, genistein, and kaempferol) with high scores were validated by various literature studies. We further built the statistical network models for identification of new anticancer indications of natural products through integration of both experimentally validated and computationally predicted drug-target interactions of natural products with known cancer proteins. We showed that the significantly predicted anticancer indications of multiple natural products (e.g., naringenin, disulfiram, and metformin) with new mechanism-of-action were validated by various published experimental evidence. In summary, this study offers powerful computational systems pharmacology approaches and tools for the development of novel targeted cancer therapies by exploiting the polypharmacology of natural products.
具有多样化学骨架的天然产物已被公认为是药物发现与开发中化合物的宝贵来源。然而,通过各种实验测定在人类蛋白质组水平上系统鉴定天然产物的药物靶点成本高昂且耗时。在本研究中,我们提出了一种系统药理学框架来预测天然产物的新药物靶点和抗癌适应症。具体而言,我们重建了一个包含751个靶点和2388种天然产物之间7314个相互作用的全球药物 - 靶点网络,并通过基于平衡子结构 - 药物 - 靶点网络的推理方法构建了预测网络模型。在交叉验证期间,预测天然产物新靶点的受试者工作特征曲线下面积高达0.96。通过各种文献研究验证了得分较高的天然产物(如白藜芦醇、染料木黄酮和山奈酚)的新预测靶点。我们进一步通过整合天然产物已实验验证和计算预测的与已知癌症蛋白质的药物 - 靶点相互作用,构建了用于鉴定天然产物新抗癌适应症的统计网络模型。我们表明,多种具有新作用机制的天然产物(如柚皮素、双硫仑和二甲双胍)的显著预测抗癌适应症已被各种已发表的实验证据所验证。总之,本研究提供了强大的计算系统药理学方法和工具,通过利用天然产物的多药理学特性来开发新型靶向癌症疗法。